---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063019"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:21:41.132928+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports Q3 2023 net loss of $2.6M; cash $14.0M

## Summary
- Net loss $2.6M ($0.42/share) vs loss $1.2M ($1.91/share) in Q3 2022; nine-month net income $2.1M on $8.3M warrant gain.
- Cash and equivalents $14.0M at Sep 30, 2023, up from $5.3M at Dec 31, 2022; runway through Sep 2024.
- Operating cash burn for nine months 2023 was $5.3M vs $10.3M in 2022, driven by lower clinical study expenses.
- Gemini preclinical data showed significant mobilization of neutrophils, monocytes, lymphocytes and upregulation of IL-10, NGAL, IL-6.
- Phase 1 clinical study of Gemini expected to begin near end of 2023.

## SEC filing metadata
- accession: 0000950170-23-063019
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/0000950170-23-063019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/revb-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063019
- JSON: https://secwatch.observer/filing/0000950170-23-063019.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063019.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported three and nine months ended September 30, 2023 results: net income $2.6 million, or $0.42 basic and diluted net loss per share.
  - Period: three and nine months ended September 30, 2023
  - Net income: $2.6 million, or $0.42 basic and diluted net loss per share
  - Result: reported results
  source text: Revelation’s net loss for the three months ended September 30, 2023 was $2.6 million, or $0.42 basic and diluted net loss per share, compared to a net loss of $1.2 million, or $1.91 basic and diluted net loss per share for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/0000950170-23-063019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.